Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study
Although HPV-16 E6 seropositivity is rare, it is generally stable once detected; thus, HPV-16 E6 antibodies may be an informative biomarker of HPV-driven oropharyngeal squamous cell carcinoma. Few men seroreverted following HPV-16 E6 seropositivity but remained close to the seropositivity cutoff; thus, cancer risk among these men is less clear.
Authors
- Danping Liu (ORCID: https://orcid.org/0000-0001-5483-6303)
- Aimée R. Kreimer (ORCID: https://orcid.org/0000-0002-6073-2591)
- Sudhir Srivastava
- Bradley Sirak
- Allan Hildesheim (ORCID: https://orcid.org/0000-0003-0257-2363)
- N. Brenner
- John Schussler (ORCID: https://orcid.org/0000-0002-8793-0766)
- Birgitta E. Michels (ORCID: https://orcid.org/0000-0001-9948-4567)
- Anna R. Giuliano (ORCID: https://orcid.org/0000-0002-5440-8859)
- Jaimie Z. Shing (ORCID: https://orcid.org/0000-0001-7064-4424)
- Tim Waterboer (ORCID: https://orcid.org/0000-0002-0616-6963)
- Wendy Wang (ORCID: https://orcid.org/0009-0007-8630-2796)
Institutions
- National Institutes of Health (US)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Moffitt Cancer Center (US)
- Information Management Services (US)
- National Cancer Institute (US)
- Associated Management Services (United States) (US)
- Department of Health and Human Services (US)
- Division of Cancer Epidemiology and Genetics
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1093/jnci/djae326
- Citations
- 5
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.90
Funders
- Department of Science and Technology, Ministry of Science and Technology, India
- National Institutes of Health
- National Cancer Institute